Neoadjuvant therapy demonstrates both safety and clinical feasibility for renal cell carcinoma patients with tumor thrombus.

ABSTRACT: While the applications of neoadjuvant therapies on patients diagnosed with renal cell carcinoma (RCC) with tumor thrombus (TT) is growing, the safety of preoperative therapies has yet to be clarified. 451 patients diagnosed with RCC with TT undergoing radical nephrectomy and thrombectomy were included. Propensity score-matched cohorts were used to investigate the safety and feasibility of neoadjuvant therapies. We compared perioperative parameters and postoperative complications. Postoperative complications were assessed within 30 days of the operation and were graded using the Clavien-Dindo grading system. A Cox regression and Kaplan-Meier curves were used to assess the impact of neoadjuvant therapies on patients' overall survival (OS) and cancer-specific survival (CSS). After 1:3 ratio p

SUBMITTER: Yu L 

PROVIDER: S-EPMC12381314 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature